Kashif Shaikh, MD
Cardiovascular Disease · Knoxville, TNNPI 1770901894
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Heartflow, Inc. at 41.0% of the total. Reporting peaked in 2024 at $3,940 and has fallen 81.2% since, to $741 in 2025.
Across 119 payments — averaging $61.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$3K
- Canon Medical Systems USA, Inc.$2K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$445
- Boston Scientific$220
- Atricure, Inc.$193
- plus $806 from 18 others
Across 44 payments — averaging $3468.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$141K
- Heartflow, Inc.$12K
What the payments were for
- Consulting fees$1,50021%
- Travel & lodging$2,16630%
- Food & beverage$3,64550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 35 | $2,996 |
| Canon Medical Systems USA, Inc. | 2 | $1,649 |
| Abbott | 7 | $1,003 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $445 |
| Boston Scientific | 8 | $220 |
| Atricure, Inc. | 4 | $193 |
| Pfizer | 10 | $157 |
| Cleerly, Inc. | 1 | $111 |
| GE HealthCare | 2 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $66 |
| Novartis | 3 | $56 |
| Amgen | 3 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Canon Medical Informatics, Inc. | 1 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Philips North America LLC | 1 | $17 |
| Sanofi | 1 | $17 |
| Edwards Lifesciences | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Bayer | 1 | $15 |
| Inogen, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$2,033
- TOSHIBA SCANNER$1,649
- Cleerly Ischemia$111
- Cleerly Labs$111
How this compares
$7,311 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $50,693 |
| Repatha SureclickEvolocumab | 41 | $29,077 |
| EntrestoSacubitril/Valsartan | 14 | $23,315 |
| JardianceEmpagliflozin | 23 | $17,023 |
| XareltoRivaroxaban | 19 | $16,350 |
| Metoprolol Succinate | 62 | $816 |
| Bumetanide | 17 | $655 |
| Amiodarone Hcl | 20 | $643 |
| Valsartan | 17 | $380 |
| ClopidogrelClopidogrel Bisulfate | 18 | $335 |
| Rosuvastatin Calcium | 45 | $332 |
| Ranolazine ErRanolazine | 13 | $296 |
| Atorvastatin Calcium | 37 | $275 |
| Carvedilol | 54 | $262 |
| Amlodipine Besylate | 55 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $50,69339 claims |
| NovartisEntresto | $56 | $23,31514 claims |
| Johnson & JohnsonXarelto | $15 | $16,35019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Knoxville
- Jeffrey JohnsonKnoxville$94K
- Neil BarryKnoxville$23K
- Joseph LiuKnoxville$22K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.